Cargando…
Use of Nanotechnology to Develop Multi-Drug Inhibitors For Cancer Therapy
Therapeutic agents that inhibit a single target often cannot combat a multifactorial disease such as cancer. Thus, multi-target inhibitors (MTIs) are needed to circumvent complications such as the development of resistance. There are two predominant types of MTIs, (a) single drug inhibitor (SDIs) th...
Autores principales: | Gowda, Raghavendra, Jones, Nathan R., Banerjee, Shubhadeep, Robertson, Gavin P. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4085796/ https://www.ncbi.nlm.nih.gov/pubmed/25013742 http://dx.doi.org/10.4172/2157-7439.1000184 |
Ejemplares similares
-
Nanotechnology-Based Histone Deacetylase Inhibitors for Cancer Therapy
por: Tu, Bin, et al.
Publicado: (2020) -
Nanotechnology of Tyrosine Kinase Inhibitors in Cancer Therapy: A Perspective
por: Russo, Eleonora, et al.
Publicado: (2021) -
Nanotechnology and Drug Delivery: An Update in Oncology
por: Jones, Tait, et al.
Publicado: (2011) -
Targeted therapy using nanotechnology: focus on cancer
por: Sanna, Vanna, et al.
Publicado: (2014) -
Liposomes and nanotechnology in drug development: focus on oncotargets
por: Kozako, Tomohiro, et al.
Publicado: (2012)